Segment, Geographical and Other Revenue Information (Tables)

9 Months Ended

Sep. 30, 2021

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands):


	Three months ended September 30, 2021						Three months ended September 30, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	28,731	$	—	$	28,731	$	8,401	$	—	$	8,401
Research and development revenue	3,853		4,185		8,038		4,604		5,380		9,984
Total revenues	32,584		4,185		36,769		13,005		5,380		18,385
Costs and operating expenses:
Cost of product revenue	6,867		—		6,867		3,642		—		3,642
Research and development(1)	5,670		8,850		14,520		5,184		6,433		11,617
Selling, general and administrative(1)	3,306		831		4,137		2,675		515		3,190
Total segment costs and operating expenses	15,843		9,681		25,524		11,501		6,948		18,449
Income (loss) from operations	$	16,741	$	(5,496)	11,245		$	1,504	$	(1,568)	(64)
Corporate costs (2)					(8,097)						(5,483)
Unallocated depreciation and amortization					(794)						(528)
Income (loss) before income taxes					$	2,354					$	(6,075)


	Nine months ended September 30, 2021						Nine months ended September 30, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	53,674	$	—	$	53,674	$	18,005	$	—	$	18,005
Research and development revenue	14,723		11,856		26,579		13,380		16,638		30,018
Total revenues	68,397		11,856		80,253		31,385		16,638		48,023
Costs and operating expenses:
Cost of product revenue	15,403		—		15,403		7,882		—		7,882
Research and development(1)	17,172		20,649		37,821		15,877		16,848		32,725
Selling, general and administrative(1)	9,294		2,052		11,346		7,395		1,728		9,123
Total segment costs and operating expenses	41,869		22,701		64,570		31,154		18,576		49,730
Income (loss) from operations	$	26,528	$	(10,845)	15,683		$	231	$	(1,938)	(1,707)
Corporate costs (2)					(24,431)						(16,526)
Unallocated depreciation and amortization					(2,220)						(1,526)
Loss before income taxes					$	(10,968)					$	(19,759)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other income (expense), net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three months ended September 30,
	2021								2020
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	1,228	$	272	$	1,516	$	3,016	$	839	$	132	$	1,013	$	1,984


	Nine months ended September 30,
	2021								2020
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	3,337	$	767	$	4,443	$	8,547	$	2,335	$	625	$	3,132	$	6,092

Schedule of Concentration Risk

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three months ended September 30,		Nine months ended September 30,
	2021	2020	2021	2020
Customer A	51%	*	29%	*
Customer B	*	13%	10%	*
Customer C	*	23%	12%	21%
Customer D	*	14%	*	22%
Customer E	*	15%	*	13%
Customer F	*	*	*	11%
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	September 30, 2021	December 31, 2020
Customer A	34%	*
Customer C	11%	32%
Customer E	14%	13%
Customer F	*	25%
* Percentage was less than 10%

Schedule of Revenues by Geographical Area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Revenues
Americas	$	7,816	$	5,841	$	18,588	$	17,972
EMEA	4,685		4,889		17,135		14,175
APAC	24,268		7,655		44,530		15,876
Total revenues	$	36,769	$	18,385	$	80,253	$	48,023

Schedule of Long-Lived Assets by Geographical Area

Identifiable long-lived assets by location was as follows (in thousands):


	September 30, 2021		December 31, 2020
United States	$	35,645	$	31,176

Schedule of Goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	As of September 30, 2021 and December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241